{
    "clinical_study": {
        "@rank": "83814", 
        "arm_group": [
            {
                "arm_group_label": "PUR118 low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PUR118 mid dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PUR118 high dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced\n      airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal\n      volunteers."
        }, 
        "brief_title": "Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or non pregnant, non lactating healthy females age 18-50 years;\n\n          -  Must be able to produce acceptable sputum sample by induction;\n\n          -  Must respond to ozone inhalation with a > 10% increase in the absolute percentage of\n             sputum neutrophils and the total neutrophils (neutrophils/gram sputum) must increase\n             by at least 50% from the sputum neutrophil count at screening;\n\n          -  Volunteer is a non-smoker or ex-smoker of at least 12 months' duration prior to\n             screening with a history of less than 1 pack per year.\n\n        Exclusion Criteria:\n\n          -  Volunteers receiving chronic medication other than oral contraceptives;\n\n          -  Screening forced expiratory volume FEV1 is < 80% of the predicted value for their\n             age, gender, height and race and/or their FEV1/FVC ration is below 70%;\n\n          -  Volunteers with significant occupational exposure to respiratory irritants or toxins\n\n          -  Upper respiratory tract infection within 30 days of the first study day, or lower\n             respiratory tract infection within the last 3 months;\n\n          -  Volunteers taking any medication that may affect the respiratory tract within 30 days\n             of the first study day;\n\n          -  Volunteers with a history of asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690949", 
            "org_study_id": "601-0005"
        }, 
        "intervention": {
            "arm_group_label": [
                "PUR118 low dose", 
                "PUR118 mid dose", 
                "PUR118 high dose"
            ], 
            "description": "inhaled PUR118, BID", 
            "intervention_name": "PUR118", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "inflammation", 
            "COPD", 
            "respiratory disease", 
            "healthy volunteers"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hannover", 
                    "country": "Germany", 
                    "zip": "30625"
                }, 
                "name": "Fraunhofer Institut fur Toxicologie und Experimentelle Medicine (ITEM)"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Single-blind Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers", 
        "overall_official": {
            "affiliation": "Pulmatrix Inc.", 
            "last_name": "John Hanrahan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in sputum cell counts and inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 hours post-initiation of ozone challenge"
            }, 
            {
                "measure": "Change from baseline in white blood cell and inflammatory biomarker counts in blood", 
                "safety_issue": "No", 
                "time_frame": "7 and 24 hours post-initiation of ozone challenge"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690949"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in pulmonary function", 
                "safety_issue": "No", 
                "time_frame": "all post-dose timepoints up to 24 hours post-initiation of ozone challenge"
            }, 
            {
                "measure": "Changes in clinical signs and symptoms from physical examination at baseline", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for an expected average of 12 weeks"
            }, 
            {
                "measure": "Changes in clinical safety laboratory tests from baseline", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for an expected average of 12 weeks"
            }, 
            {
                "measure": "Changes in vital signs from baseline", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for an expected average of 12 weeks"
            }, 
            {
                "measure": "Changes in ECG from baseline", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for an expected average of 12 weeks"
            }, 
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for an expected average of 12 weeks"
            }
        ], 
        "source": "Pulmatrix Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pulmatrix Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}